New perspectives on the approach to patients with atypical Hemolytic Uremic Syndrome candidates for renal transplantation

Atypical hemolytic uremic syndrome (aHUS) is one of the most challenging diseases for a nephrologist, with high rates of progression to end- -stage kidney disease (ESKD) and post-transplant recurrence. Complement dysregulation has been found in up to 70% of cases, which can be hereditary or acquired. Over the last few years, knowledge of the pathogenesis of aHUS has greatly increased, with the unravelling of the complement’s role, providing not only the chance for individualized post-transplant recurrence risk assessment, but also the possibility of a highly effective treatment through pharmacological C5-9 blockade with eculizumab. The overall outcome and prognosis of patients with aHUS has dramatically improved since the approval of this drug in 2011, allowing renal transplant to be a much safer option for these patients. Our aim was to present a proposal for the management of patients with aHUS, candidates for renal transplantation, in the light of the most recent studies.

[1]  C. Reutelingsperger,et al.  Functional and Genetic Landscape of Complement Dysregulation Along the Spectrum of Thrombotic Microangiopathy and its Potential Implications on Clinical Outcomes , 2021, Kidney international reports.

[2]  A. Java.  Peri- and Post-operative Evaluation and Management of Atypical Hemolytic Uremic Syndrome (aHUS) in Kidney Transplantation. , 2020, Advances in chronic kidney disease.

[3]  F. Petitprez,et al.  Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. , 2019, Journal of the American Society of Nephrology : JASN.

[4]  G. Ardissino,et al.  Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome , 2018, Kidney international reports.

[5]  Arvind Bagga,et al.  Atypical Hemolytic‐Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment , 2018, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[6]  P. Balmer,et al.  Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination , 2018, Human vaccines & immunotherapeutics.

[7]  J. Wetzels,et al.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use , 2018, Pediatric Nephrology.

[8]  B. Faria,et al.  Portuguese consensus document statement in diagnostic and management of atypical hemolytic uremic syndrome , 2018 .

[9]  J. Wetzels,et al.  Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  P. Ruggenenti,et al.  Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  N. Sheerin,et al.  Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). , 2016, Immunobiology.

[12]  G. Remuzzi,et al.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies , 2015, Kidney international.

[13]  S. Rodríguez de Córdoba,et al.  An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. , 2015, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[14]  N. Junglee,et al.  Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. , 2014, Clinical nephrology.

[15]  G. Ardissino,et al.  Cryptic Activity of Atypical Hemolytic Uremic Syndrome and Eculizumab Treatment , 2014, Pediatrics.

[16]  C. Legendre,et al.  Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. , 2013, Transplantation reviews.

[17]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[18]  John Hwa,et al.  Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome , 2013, Nature Genetics.

[19]  N. Kamar,et al.  Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  V. Frémeaux-Bacchi,et al.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies , 2012, Nature Reviews Nephrology.

[21]  C. Legendre,et al.  New insights into postrenal transplant hemolytic uremic syndrome , 2011, Nature Reviews Nephrology.

[22]  R. Stefanov,et al.  Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[23]  S. D. Subba Rao,et al.  Atypical hemolytic uremic syndrome. , 2002, Indian pediatrics.

[24]  Oleg O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  J. Cecka.  The UNOS Scientific Renal Transplant Registry. , 1999, Clinical transplants.

[26]  H. Tiddens,et al.  Haemolytic uraemic syndrome. , 1979, Paediatrician.